Highlights Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Real-time Estimate Cboe BZX Other stock markets 14:41:57 2024-05-10 EDT			5-day change	1st Jan Change
4.685 ^USD	-1.99%		+7.18%	+80.27%

05-07	Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	MT
05-01	Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	04-01	MT
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials	03-22	MT
Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	03-22	CI
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	03-18	MT
Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic	03-14	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	03-05	MT
Summit Therapeutics Q4 Loss Widens	02-20	MT
Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-20	CI
Summit Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-20	CI
North American Morning Briefing : Earnings Back in -2-	02-20	DJ
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference	01-08	CI
Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Summit Therapeutics' Q2 Net Loss Narrows	23-08-09	MT
Summit Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Summit Therapeutics Inc. Announces Data for its Novel, Potential First-In-Class Investigational Bispecific Antibody,ivonescimab	23-06-01	CI
Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab	23-05-09	CI
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab	23-05-03	CI
Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Highlights

Filters